On September 18, 2025, Canada’s Drug Agency (CDA) launched its new strategy to improve the appropriate prescribing and use of prescription medications in Canada. The strategy, titled “A Prescription for Action: A Pan-Canadian Strategy for Advancing the Appropriate Use of Prescription Medications,” provides a 5-year plan to foster a unified national approach that promotes safer, more effective medication use and strengthens health system sustainability.
The strategy sets out four strategic priorities:
- Partnerships and Program Development: Develop, enhance, and implement appropriate use initiatives with partners across Canada.
- Connect: Strengthen networks and provide comprehensive information about appropriate use.
- Strategy and Policy: Develop evidence-informed advice and recommendations for decision-makers about the adoption and implementation of appropriate use policies and strategic initiatives.
- Evaluation and Reporting: Assess project outcomes and communicate impact clearly.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
2025 highlights in Canadian life sciences IP and regulatory law
In 2025, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
New PMPRB Chairperson and PMPRB releases January 2026 NEWSletter
On January 29, 2026, the Minister of Health announced Anie Perrault, former Vice-Chairperson, as Chairperson of the Patented Medicine Prices Review Board (PMPRB) until August 9, 2028.Read More -
Canada’s Drug Agency announces consultation on streamlined review process and new reconsideration/resubmission procedures
On January 29, 2026, Canada’s Drug Agency (CDA) published Improvements to the Drug Reimbursement Review Process, which includes a section for consultation on proposed changes to the reimbursement re...Read More
